Breaking News

Innovent Biologics Expand Capabilities

Invests $25 million in pipeline and manufacturing plant

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Innovent Biologics, Inc. is investing $25 million to continue the expansion of its pipeline and manufacturing capabilities in Suzhou, China. The financing is provided by Lilly Asia Ventures, part of Eli Lilly, and from Fidelity Biosciences and Fidelity Growth Partners Asia.     Innovent currently has a GMP pilot plant for the production of clinical trial material and is building a new campus in Suzhou. It will include laboratories and offices, and will house a commercial manufacturing plant with...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters